TY  - JOUR 
AU  - Li, Jihong
AU  - Fukase, Yoshiyuki
AU  - Shang, Yi
AU  - Zou, Wei
AU  - Muñoz Félix, José Manuel
AU  - Buitrago, Lorena
AU  - van Agthoven, Johannes
AU  - Zhang, Yixiao
AU  - Hara, Ryoma
AU  - Tanaka, Yuta
AU  - Okamoto, Rei
AU  - Yasui, Takeshi
AU  - Nakahata, Takashi
AU  - Imaeda, Toshihiro
AU  - Aso, Kazuyoshi
AU  - Zhou, Yuchen
AU  - Locuson, Charles
AU  - Nesic, Dragana
AU  - Duggan, Mark
AU  - Takagi, Junichi
AU  - Vaughan, Roger D.
AU  - Walz, Thomas
AU  - Hodivala-Dilke, Kairbaan M.
AU  - Teitelbaum, Steven L.
AU  - Arnaout, M. Amin
AU  - Filizola, Marta
AU  - Foley, Michael A.
AU  - Coller, Barry S.
PY  - 2019
SN  - 0361-7742
UR  - http://hdl.handle.net/10366/155142
AB  - [EN]The integrin αVβ3 receptor has been implicated in several important diseases, but no antagonists are approved for human therapy. One possible limitation of current small-molecule antagonists is their ability to induce a major conformational change...
LA  - eng
PB  - ACS Publications
KW  - Integrin
KW  - αVβ3
KW  - Osteoclast
KW  - Angiogenesis
KW  - Breast Neoplasms
KW  - Vaginal Smears
KW  - Cytodiagnosis
KW  - Adult
KW  - Ovarian Neoplasms
KW  - Humans
KW  - Uterine Neoplasms
KW  - Middle Aged
KW  - Neoplasms
KW  - Uterine Cervical Neoplasms
TI  - Novel pure αVβ3 integrin antagonists that do not induce receptor extension, prime the receptor, or enhance angiogenesis at low concentrations
DO  - 10.1021/acsptsci.9b00041
T2  - ACS Pharmacology & Translational Science
VL  - 2
M2  - 387
ER  -